Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts

Paolo Strati, Guillermo Garcia-Manero, Chong Zhao, Tapan Kadia, Gautam Borthakur, Marina Konopleva, Naval Daver, Courtney D. DiNardo, Nicholas J. Short, Musa Yilmaz, Kiran Naqvi, Yesid Alvarado, Sherry A. Pierce, Jorge Cortes, Carlos Bueso-Ramos, Hagop Kantarjian, Farhad Ravandi

Research output: Contribution to journalLetter

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)E188-E190
JournalAmerican Journal of Hematology
Volume94
Issue number7
DOIs
StatePublished - Jul 2019

ASJC Scopus subject areas

  • Hematology

Cite this

Strati, P., Garcia-Manero, G., Zhao, C., Kadia, T., Borthakur, G., Konopleva, M., Daver, N., DiNardo, C. D., Short, N. J., Yilmaz, M., Naqvi, K., Alvarado, Y., Pierce, S. A., Cortes, J., Bueso-Ramos, C., Kantarjian, H., & Ravandi, F. (2019). Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. American Journal of Hematology, 94(7), E188-E190. https://doi.org/10.1002/ajh.25490